Eli Lilly and Company (LLY)
NYSE • Healthcare
May 20, 2026 at 16:00 UTC
About Eli Lilly and Company
Eli Lilly and Company is a pharmaceutical manufacturer that discovers, develops, and supplies medicines for conditions managed over long periods and in specialized care. The model connects science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use in clinics and hospitals. The company’s priority is continuity — steady supply, clear labeling, and guidance that helps clinicians match therapy to patients. Access programs and country teams adapt to local frameworks while holding to shared safety standards. Digital tools and field support aim to simplify onboarding and monitoring without adding burden to care teams. Within the healthcare sector, Lilly’s role is to make new options feel dependable in daily practice, while continuing to invest in pipelines that can address unmet medical need.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Eli Lilly and Company's Technical Indicators Summary
LLY presents a bullish technical profile with solid momentum and broad moving-average support. The MACD and RSI show constructive momentum while price trades above short-, medium- and long-term averages, including the 200-day, indicating broad-based strength. ADX is modest, suggesting the trend is present but not extreme, and volatility is moderate with an ATR that is small relative to the share price. On-balance volume is positive and the pivot sits below current levels, reinforcing the constructive setup. Technical takeaway: Bullish — momentum and moving-average alignment support the uptrend.
| Indicator | Value |
|---|---|
RSI (14) | 62.21 |
Stochastic %K (14, 3, 3) | 89.45 |
CCI (20) | 88.87 |
WPR (14) | -1.12 |
Momentum (10) | 32.54 |
MFI | 72.75 |
MACD Level (12, 26) | 21.02 |
Bollinger Bands | $849.77 - $1057.78 |
ATR (14) | $30.19 (2.96%) |
ADX (14) | 17.97 |
OBV | 88,214,134 |
Classic Pivot Point | $989.99 |
Fibonacci Pivot Point | $989.99 |
Exponential Moving Averages | $905.80 - $989.61(5 indicators) |
Simple Moving Averages | $924.03 - $993.13(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The day concluded on a slightly softer note, with LLY maintaining a small -0.30% downside gap and finishing at about 1018.34. The session wrapped with neutral sector performance (-0.12%), offering little macro push or pull. LLY eases modestly as TuneLab AI collaboration expands, reinforcing Lilly's AI-led R&D push.
Price Change
from $1018.14 close
+$0.01
Trading Volume
Below avg (3.1M)
2M
vs S&P 500 Today
Strong Underperformance
-4.12%
52-Week Position
Upper range
77.3%
Updated: May 20, 2026 at 20:13 UTC
Quote Summary
LLY Headlines
Health Care Lags SPY At 24-Year Low
May 18, 2026
Amgen Rides Renewed GLP-1 Obesity Momentum
April 9, 2026
Vanguard ETFs Face Rotation and Strategy Shifts
April 4, 2026
US Stocks Rise as Growth Sectors Lead
March 31, 2026